Lv1
80 积分 2022-08-17 加入
T Cell Responses to Individualized Neoantigen Therapy mRNA-4157 (V940) Alone or in Combination With Pembrolizumab in the Phase 1 KEYNOTE-603 Study
5个月前
已完结
Cancer-Associated Hypercalcemia
7个月前
已完结
驱动基因阳性晚期非小细胞肺癌免疫治疗专家共识(2023版)
11个月前
已完结
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
1年前
已完结
Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
1年前
已完结
Next-generation psychedelics: should new agents skip the trip?
1年前
已关闭
A phase II study of efficacy and safety of the MEK inhibitor tunlametinib in patients with advanced NRAS-mutant melanoma
1年前
已完结
Model‐Informed Drug Development: Current US Regulatory Practice and Future Considerations
1年前
已完结
Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma
1年前
已完结
Chemotherapy with or without avelumab followed by avelumab maintenance versus chemotherapy alone in patients with previously untreated epithelial ovarian cancer (JAVELIN Ovarian 100): an open-label, randomised, phase 3 trial
1年前
已完结
Death-associated protein kinase 1 correlates with podocyte apoptosis and renal damage and can be mediated by miR-361
皖公网安备34019202002308
